Vincent Lo Re III, M.D., M.S.C.E.

faculty photo
Associate Professor of Medicine
Department: Medicine
Graduate Group Affiliations

Contact information
Center for Clinical Epidemiology and Biostatistics
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Fax: 215-349-5111
B.S. (Chemistry)
Georgetown University, 1992.
M.D. (Medicine)
University of Pennsylvania, 1997.
M.S.C.E. (Pharmacoepidemiology)
University of Pennsylvania, 2005.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research Interests
- Hepatic and non-hepatic outcomes of chronic hepatitis B and C, particularly among patients with HIV infection
- Adherence to hepatitis C virus therapy
- Hepatotoxicity of medications
- Evaluation of clinical outcomes
- Population-based and administrative databases

Key Words
HIV/viral hepatitis coinfection; hepatitis B; hepatitis C; HIV/AIDS; epidemiology; clinical outcomes; pharmacoepidemiology

Description of Research
Dr. Lo Re’s research focuses on clinical outcomes of chronic viral hepatitis infection in HIV-infected patients. He is conducting epidemiologic studies to examine novel risk factors for decompensated cirrhosis among HIV/hepatitis C-coinfected patients and is working to develop and internally validate a clinical predictive index to stratify HIV/hepatitis C patients according to their risk of progression to hepatic decompensation. He has also examined the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients. Additional studies are examining non-hepatic outcomes of chronic viral hepatitis infection in HIV, particularly abnormalities in bone mineral density and fractures.

Dr. Lo Re also evaluates clinical outcomes of hepatitis therapy in the setting of HIV. Recent work has examined the incidence and risks factors for anemia and weight loss during hepatitis C therapy among HIV-infected patients. Another active area of research is adherence to combination pegylated interferon and ribavirin hepatitis C therapy, specifically examining the levels of adherence required for maximal hepatitis C suppression and risk factors for poor adherence to these therapies.

Methodologic interests include use of population-based databases for epidemiologic research, ascertainment and adjudication of clinical outcomes, and pharmacoepidemiology.

Description of Clinical Expertise

Viral hepatitis; HIV/hepatitis C coinfection; HIV/hepatitis B coinfection; drug-induced liver injury

Selected Publications

Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR: Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol 14(7): 1035-4, July 2016.

Lo Re V 3rd, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Haynes K, Roy JA, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med 129(3): 283-91, e5, March 2016.

Lo Re V 3rd, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, Leidl KBF, Reddy KR, Nezamzadeh MS, Roy J, Sha D, Marks AR, De Boer J, Schneider JL, Strom BL, Corley DA: Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of Hy's Law and a new prognostic model. Clin Gastroenterol Hepatol 13(13): 2360–8, December 2015.

Goldberg DS, Forde KA, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA, Lo Re V 3rd: Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology 148(7): 1353-61, June 2015.

Lo Re V 3rd, Kallan MJ, Tate J, AR Localio, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 160(6): 369-79, March 2014.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd: Incidence and risk factors for incomplete hepatitis B virus DNA suppression in HIV/hepatitis B-coinfected patients receiving tenofovir-based antiretroviral therapy. J Viral Hepat 21(4): 288-96, Apr 2014.

Lim JK, Tate J, Fultz SL, Goulet JL, Rimland D, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Fiellin DA, Justice AC, Lo Re V 3rd: Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus–infected, and uninfected patients. Clin Infect Dis 58(10): 1449-58, May 2014.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol 61(2): 210-8, June 2014.

Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR: Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV coinfection. Hepatology 56(5): 1688-98, November 2012.

Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Relationship between adherence to hepatitis C virus therapy and virologic outcomes. Ann Intern Med 155(6): 353-60, September 2011.

back to top
Last updated: 04/19/2021
The Trustees of the University of Pennsylvania